new medicines, digital health, and cancer innovation
Boston, MA
Joined February 2021
- Tweets20
- Following39
- Followers173
- Likes284
Thomas Hwang, MD retweeted
NEW with @LizzyLaw_: The Trump administration is rolling out a program aimed at getting Medicare to match drug prices in other countries for certain high-cost drugs
Pharma companies that cut deals with the admin expected to be exempt
wsj.com/health/pharma/trump-…
Thomas Hwang, MD retweeted
New US Medicare pricing policies could reshape global pharmaceutical markets, potentially driving up prices and delaying medicine launches worldwide, study suggests.
Find out more: spkl.io/60127RvPo
ALT Research in context panel for a paper published in The Lancet entitled \"Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study\". Copyright: 2026 Elsevier Ltd. All rights reserved.
Thomas Hwang, MD retweeted
Our viewpoint about the new @MedicareGov Payment Policy on Drug shortages in @JAMAHealthForum with @thomasmd + @KNVokinger
We propose some reforms CMS and policymakers should pursue to ensure greater stability in generic medicine availability
-creation of a quality-based purchasing program,
-revising inflation-linked rebates for generic medicines,
-extension to outpatient cancer therapies,
-expanded drug importation for products in shortage.
@DanaFarber @ETH_en @UZH_en
Link: jamanetwork.com/journals/jam…
Thomas Hwang, MD retweeted
Perspective by Thomas J. Hwang, MD (@thomasmd), Quoc-Dien Trinh, MD, MBA (@qdtrinh), and Kerstin N. Vokinger, MD, JD, PhD (@KNVokinger): The Risks of Pharmaceutical Tariffs for Generic Drug Availability nej.md/3Vy6W9U
#HealthPolicy
ALT Perspective "Broad tariffs on generic drugs are unlikely to achieve the policy intent of safeguarding national security from geopolitical threats to the U.S. medicine supply." "The Risks of Pharmaceutical Tariffs for Generic Drug Availability" by Thomas J. Hwang, M.D., Quoc-Dien Trinh, M.D., M.B.A., and Kerstin N. Vokinger, M.D., J.D., Ph.D.
Thomas Hwang, MD retweeted
Congrats to Thomas Hwang, MD (@thomasmd) of @DanaFarber and @BWHUrology on being recognized as a 2023 #StatWunderkind @statnews @DanaFarber_GU @DrChoueiri
ms.spr.ly/60129vhHq
new piece @JAMAOnc on new therapies for BCG-unresponsive NMIBC and modernizing FDA guidance on trial design. @MA_Preston @daviesbj
jamanetwork.com/journals/jam…
Thank you @Nature @maxdkozlov for covering our NEJM piece and the new law on diversity in clinical trials. Looking forward to presenting at Multi-Disciplinary conference @DanaFarber_GU and discussing implications for trialists.
nature.com/articles/d41586-0…
Thomas Hwang, MD retweeted
The FDA will soon require companies and researchers to detail how they plan to enroll a diverse clinical-trial participant pool before they begin late-stage trials.
Read more in my latest for @Nature, with @millerbioethics, @Marianfknight, @thomasmd:
nature.com/articles/d41586-0…
Thomas Hwang, MD retweeted
#Viewpoint proposes restructuring @WHO's Model List of Essential Medicines to formally remove consideration of cost and cost-effectiveness from the expert committee reviews of clinical effectiveness, safety, and public health value. ja.ma/3syL1AE
Thomas Hwang, MD retweeted
Recent House legislation would codify recommendations that trial sponsors design diversity plans for enrollment, but it does not provide a mechanism for remedying inadequate progress. nej.md/3SUxkrk
Thanks @Nicole_DeFeudis for talking with me about our NEJM piece and proposed framework to ensure more representative clinical trials. in @endpts
endpts.com/are-incentives-ne…
Thomas Hwang, MD retweeted
Important @NEJMPerspec from @thomasmd at @PORTAL_Research on improving quality and generalizability of clinical trials!: New Federal Incentives for Diversity in Clinical Trials | NEJM nejm.org/doi/full/10.1056/NE…
Thank you @cecelou18 for talking with me in Bloomberg on reforms to accelerated approval; earlier in @Medscape @endpts (more in recent work @TheLancet @JAMAHealthForum)
news.bloomberglaw.com/health…
Thomas Hwang, MD retweeted
Thank you @equitablegrowth for including our project (w/ @joshfeng89 & @thomasmd) in this year’s funding round! It’s a privilege to be part of this great group of researchers
Congratulations to our just-announced class of 2022 #EGgrantee(s)! 🎉🎊 Get to know all 42 of them: equitablegrowth.org/equitabl… #EGgrantee2022
Thomas Hwang, MD retweeted
New study: No of drug indications granted accelerated approval increased in US&Europe, only approx 1/3 with high value. @UZH_ch, @PORTAL_Research, @BWHUrology, @thomasmd
jamanetwork.com/journals/jam…
Funded by @snsf_ch, @Krebs_Forschung
Swiss national news: srf.ch/news/schweiz/wirkung-…
Thanks Jeannie @bloomberglaw for talking with me about our study in @JAMAHealthForum
@KNVokinger
news.bloomberglaw.com/pharma…
Thomas Hwang, MD retweeted
Viewpoint describes the provisions and limitations of #prescriptiondrugpricing reforms enacted by US Congress as part of the #InflationReductionAct in August 2022. ja.ma/3Axy5Qs
Thank you very much @DrChoueiri @DanaFarber_GU for a great discussion + hosting me today
Thomas Hwang, MD retweeted
New EU regulation on health technology assessment of cancer medicines: authors suggest to adopt existing validated value frameworks, notably the ESMO-MCBS as a common foundation for evaluation.
thelancet.com/journals/lanon…
